Connect with us

Health

Insys Therapeutics Inc (NASDAQ:INSY) Addresses Arizona Attorney General Grievance

Published

on

Insys Therapeutics Inc

In the first week of September, Insys Therapeutics Inc (NASDAQ:INSY) management reported that they continue to reiterate their initiatives to be part of the offering to the opioid crisis by focusing on helping patients and advancing alternative pain drugs in their research and development. The solutions to this grave national challenge need serious commitment by, and synchronization between, manufacturers, prescribers, patients, governmental authorities and other stakeholders in the healthcare sector.

The details

Encompassed in company’s desire to bring solutions is Insys continuing commitment to take accountability for actions by its former employees and establish high standards of integrity from its current staff. Recent statements made pertaining to the Arizona Attorney General’s probe of their firm lack context and factual accuracy, especially as they link to the roots of the opioid crisis in Arizona. The company had set some of the pertinent facts for consideration.

Insys continue to cooperate with the probe by the Arizona Attorney General office, as it has done and will continue to follow with each governmental authority. The assertions made in the Arizona Attorney General’s complaint link to former staff and physicians that are no longer linked with Insys or its speaker bureau.

By several projections, the national opioid crisis started over a decade and a half earlier. SUBSYS® was introduced in March 2012. In 2016, it formed less than 1,450 prescriptions in Arizona when compared to more than 4.7 million opioid prescriptions in Arizona during the comparable period. In other words, last year, SUBSYS constituted less than 0.03% of all opioid treatments in Arizona.

A doctor is not allowed to prescribe, a pharmacy is not allowed to dispense, and a patient is not allowed to get any Transmucosal Immediate Release Fentanyl product, unless each of them is registered in the FDA required TIRF Risk Evaluation and Mitigation Strategy program. This program strives to restrict the risk of abuse and misuse by limiting prescriptions to appropriate patients, stopping inappropriate conversions between drugs and educating patients, druggists and prescribers about possibility for abuse, overdose and addiction of TIRFs, as well as the marker for these offerings.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement